PharmedOUT is a Georgetown University Medical Center project that advances evidence-based prescribing and educates health care professionals and students about pharmaceutical and medical device marketing practices. PharmedOUT provides educational slideshows, videos, events, and information about CME courses free of industry sponsorship.

Resource Highlights

A PharmedOut Webinar:
Institutional Corruption and Clinical Practice Guidelines

We introduce to you PharmedOut's very first online webinar, featuring Lisa Cosgrove, PhD and Joel Lexchin, MD. Please join us on Monday, August 17 at 4:00PM EDT for an enlightening conversation about industry influence on clinical practice guidelines.

According to the Institute of Medicine, clinical practice guidelines (CPGs) are systematically developed statements to assist practitioners and patient decisions about appropriate health care for specific circumstances; however, CPGs are not immune to industry influence. Lisa Cosgrove will present her research on institutional corruption and its direct effects on clinical practice guidelines in psychiatry and Joel Lexchin will focus on how financial conflicts of interests bias guidelines.

The presentations will be followed by a Q&A moderated by Dr. Fugh-Berman.

Lisa Cosgrove PhD is a clinical psychologist and Professor at the University of Massachusetts, Boston, where she teaches courses on psychiatric diagnosis and psychopharmacology. She is a former Research Fellow at the Edmond J. Safra Center for Ethics, Harvard University (2010-2015). Her research addresses the ethical and medical-legal issues that arise in organized psychiatry because of academic-industry relationships. Lisa has published articles, and book chapters, and has co-edited casebooks on these topics and is co-author, with Robert Whitaker, of Psychiatry under the Influence: Institutional Corruption, Social Injury, and Prescriptions for Reform. She received a 2015 Distinguished Publication Award, given by the Association for Women in Psychology, for her paper (with Emily Wheeler), “Industry’s colonization of psychiatry.” She is also the PI for an RO3 NIH grant (through the Agency for Healthcare and Research Quality), “A cross-sectional study of clinical practice guidelines for depression: Is guideline quality associated with independence from industry?”

Joel Lexchin received his MD from the University of Toronto in 1977 and for the past 32 years has been an emergency physician at the University Health Network. He taught health policy in the School of Health Policy and Management at York University from 2001 to 2016 and is now a Professor Emeritus at York. He has been a consultant on pharmaceutical issues for the province of Ontario, various arms of the Canadian federal government, the World Health Organization, the government of New Zealand and the Australian National Prescribing Service. He is a frequent outspoken critic of the pharmaceutical industry and the way that Health Canada regulates drugs. His book, Private Profits Versus Public Policy: the Pharmaceutical Industry and the Canadian State, was published by University of Toronto Press in September 2016 and his book Doctors in Denial: Why Big Pharma and the Canadian Medical Profession Are Too Close For Comfort was published by Lorimer in 2017.

Find the status of state legislation to address prescription drug costs with this interactive map. Use the category buttons to search by type of legislation and roll over a state to view its pending drug legislation. Download or view a chart listing 2020 legislation by state. View state action in 2019, 2018, 2017, and 2015-2016. Email information about new bills or legislative action to Sarah Lanford.

Pharma-free CME

We provide access to free online CME from the CDC, TCEO, NIH, AHRQ, and more.

Dr. Fugh-Berman and the Opioid Epidemic

The Washington Post released a documentary and companion article on the opioid epidemic and the immense corporate marketing push behind it. Dr. Fugh-Berman appears at the 2:33 minute mark commenting on how industry persuaded physicians to prescribe opioids.